Th1Th17_CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment

Table 2

Analysis of clinical and radiologic characteristics of the patients after 12 months of treatment.

	DMF cohort ()			Fingolimod cohort ()
	Baseline	+12 months	value	Baseline	+12 months	value
ARR mean (SD)
Total patients	1.5 (1.01)	0.14 (0.35)		1.56 (1.18)	0.61 (0.84)
Naive patients	1.6 (0.8)	0.06 (0.26)		1.72 (1.01)	0.83 (0.86)
Treated patients	1.6 (1.4)	0.28 (0.48)		1.4 (1.35)	0.46 (0.81)
Relapse-free patients (no. of patients (%))		19 (86.4)			25 (62.5)
Progression-free patients (no. of patients (%))		21 (95)			34 (85)
Free MRI activity (no. of patients (%))		15 (79)			25 (64)

DMF: dimethyl fumarate; ARR: annualized relapse rate.